Barcelona (Spain), December 4, 2025. ADmit Therapeutics today announced that it has obtained the CLIA (Clinical Laboratory Improvement Amendments) Certificate. This accreditation, granted by the US Centers for Medicare & Medicaid Services (CMS), confirms compliance with the most stringent standards for analytical quality and reliability.
Obtaining CLIA certification is a crucial milestone that transforms ADmit Therapeutics into a provider with full regulatory validity for the US market.
“This certification is not just a seal of quality; it is an essential commercial passport that guarantees the analytical excellence of our processes and allows us to offer our advanced technology, the MAP-AD® Test, to patients and healthcare providers in the United States,” stated Marta Barrachina, CEO of the company.
The CLIA certificate ensures that all analyses and validation of results performed by ADmit Therapeutics on samples from US patients comply with U.S. federal requirements regarding accuracy, reliability, and timeliness.
This accreditation underscores ADmit Therapeutics’ commitment to the highest international quality standards and its position as a strategic global partner in diagnostics and research.
The CLIA certification adds to the CAP accreditation clearance in 2024 and strengthens the laboratory’s capacity to offer services of the MAP-AD® Test in the US market.
What is CLIA?
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) and its implementing regulations at 42 CFR Part 493 are federal laws and regulations that apply to all U.S. and CLIA-certified international laboratories or sites that test specimens from humans (e.g., blood, tissue, and body fluid) to assess health or to diagnose, prevent, or treat disease. The Centers for Medicare & Medicaid Services (CMS), in collaboration with the Centers for Disease Control (CDC) and the Food & Drug Administration (FDA), support the CLIA program to ensure quality laboratory testing.
